Life sciences

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Abeona Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ABEO

Tuesday, November 19, 2019 - 1:17am

NEW YORK, Nov. 18, 2019 /PRNewswire/ --Pomerantz LLP announces that a class action lawsuit has been filed against Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ:ABEO) and certain of its officers.

Key Points: 
  • NEW YORK, Nov. 18, 2019 /PRNewswire/ --Pomerantz LLP announces that a class action lawsuit has been filed against Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ:ABEO) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Abeona is a clinical-stage biopharmaceutical company that purports to develop cell and gene therapies for life-threatening rare genetic diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

The global cell and gene therapy market is growing at a CAGR of over 24% during the forecast period 2018-2024

Monday, November 18, 2019 - 8:15pm

The global cell and gene therapy market is growing at a CAGR of over 24% during the forecast period 20182024.

Key Points: 
  • The global cell and gene therapy market is growing at a CAGR of over 24% during the forecast period 20182024.
  • The following factors are likely to contribute to the growth of the cell and gene therapy market during the forecast period:
    The study considers the present scenario of the cell and gene therapy market and its market dynamics for the period 2018?2024.
  • Cell and Gene Therapy Market: Segmentation
    This research report includes detailed market segmentation by product, application, end-user, and geography.
  • The global cell therapy market is growing at a steady rate, and this trend is expected to continue during the forecast period due to the increased patient base with a wide range of diseases/ailments.

New England Biolabs® Announces the Donald G. Comb Honorary Lectureship Series in Celebration of Company Founder

Monday, November 18, 2019 - 7:34pm

The University of California, Berkeley's, Eva P. Nogales, a pioneer in the application of cryogenic electron microscopy (Cryo-EM), will kick off the Donald G. Comb Honorary Lectureship series at New England Biolabs, in Ipswich, MA, on November 20th, 2019.

Key Points: 
  • The University of California, Berkeley's, Eva P. Nogales, a pioneer in the application of cryogenic electron microscopy (Cryo-EM), will kick off the Donald G. Comb Honorary Lectureship series at New England Biolabs, in Ipswich, MA, on November 20th, 2019.
  • Cryo-EM is a technique that bridges the gap between molecules and cells, allowing the study of large protein complexes that operate in living cells.
  • "Dr. Nogales is a worthy choice for our inaugural Donald G. Comb Honorary Lectureship," said Thomas C. Evans, Jr., Ph.D. and Executive Director of Research.
  • NEW ENGLAND BIOLABS and NEB are registered trademarks of New England Biolabs, Inc.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/new-england-biolabs-announces-the-donald-g-comb-honorary-lectureship-series-in-celebration-of-company-founder-300960216.html

Morphic to Present at the Jefferies 2019 London Healthcare Conference

Monday, November 18, 2019 - 9:15pm

WALTHAM, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, todayannounced that Praveen Tipirneni, M.D., president and chief executive officer, is scheduled to present a corporate overview at the Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019, at 1:20 p.m. GMT, in London.

Key Points: 
  • WALTHAM, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, todayannounced that Praveen Tipirneni, M.D., president and chief executive officer, is scheduled to present a corporate overview at the Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019, at 1:20 p.m. GMT, in London.
  • A live webcast of the presentation will be available on the Investors section of Morphics website at https://www.morphictx.com .
  • An archived replay will be available on the companys website for a period of 90 days after the conference.
  • Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.

Trevena to Present at the Stifel 2019 Healthcare Conference

Monday, November 18, 2019 - 10:05pm

CHESTERBROOK, Pa., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer, will present at the Stifel 2019 Healthcare Conference, sponsored by Stifel, to be held at the Lotte New York Palace Hotel in New York City on Wednesday, November 20, 2019 at 8:35 a.m. EST.

Key Points: 
  • CHESTERBROOK, Pa., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer, will present at the Stifel 2019 Healthcare Conference, sponsored by Stifel, to be held at the Lotte New York Palace Hotel in New York City on Wednesday, November 20, 2019 at 8:35 a.m. EST.
  • A live audio webcast and archived replay of the presentation will be available on Trevenas investor relations website at https://investors.trevena.com/ .
  • Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
  • Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders.

Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference

Monday, November 18, 2019 - 9:05pm

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 4:40 p.m. GMT in London, UK.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 4:40 p.m. GMT in London, UK.
  • Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation.
  • For more information about Sangamo, visit www.sangamo.com .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20191118005718/en/

Vium and Biomere Announce Collaboration to Provide Preclinical Research Services using Vium's Smart Cage Technology

Monday, November 18, 2019 - 5:00pm

At the conference, Biomere will feature Vium's innovative digital biomarkers now available as part of Biomere's unique preclinical service offering around specialty animal models.

Key Points: 
  • At the conference, Biomere will feature Vium's innovative digital biomarkers now available as part of Biomere's unique preclinical service offering around specialty animal models.
  • "The Vium alliance allows Biomere to enhance existing service offerings providing additional assessments in a variety of pharmacological models," said April Hall, executive vice president of Biomere.
  • "Vium is committed to bringing innovative technology to drug development," said Wendel Barr, CEO of Vium.
  • The Vium Digital Vivarium, Vium Cloud, and online Research Suite empower scientists to optimize advances in bioengineered research models in ways previously not possible.

Antisense Therapeutics Announces Additional preliminary data from the ATL1102 Phase II DMD trial presented at the 2019 Action Duchenne International Conference

Monday, November 18, 2019 - 5:00pm

MELBOURNE, Australia, Nov.18, 2019 /PRNewswire/ --Antisense Therapeutics (ASX: ANP/OTC: ATHJY) is pleased to advise that additional preliminary data analyses from the seven patients who have completed their 24 weeks of dosing in the ATL1102 Phase II DMD clinical trial was presented by Dr Ian Woodcock, the Principle Investigator of the ATL1102 Phase II trial at the 2019 Action Duchenne International Conference, Hinkley, UK on 15 November 2019.

Key Points: 
  • MELBOURNE, Australia, Nov.18, 2019 /PRNewswire/ --Antisense Therapeutics (ASX: ANP/OTC: ATHJY) is pleased to advise that additional preliminary data analyses from the seven patients who have completed their 24 weeks of dosing in the ATL1102 Phase II DMD clinical trial was presented by Dr Ian Woodcock, the Principle Investigator of the ATL1102 Phase II trial at the 2019 Action Duchenne International Conference, Hinkley, UK on 15 November 2019.
  • PUL is a functional scale specifically designed for assessing upper limb function in DMD with the aim of reflecting the proximal to distal progression of muscle weakness typically observed in DMD.
  • It includes three domains (shoulder, mid- and distal), each including items exploring activities easily related to activities of daily living that both patients and clinicians regard as relevant.
  • The ATL1102 Phase II DMD trial remains ongoing with dosing in all patients to be completed this month.

Caribou Biosciences Announces New Methods to Harness Type I CRISPR-Cas Systems for Genome Engineering in Human Cells

Monday, November 18, 2019 - 6:19pm

Caribou Biosciences, Inc., a leading CRISPR genome editing company, announced the publication of a new study demonstrating human genome engineering with Type I CRISPR-Cas systems.

Key Points: 
  • Caribou Biosciences, Inc., a leading CRISPR genome editing company, announced the publication of a new study demonstrating human genome engineering with Type I CRISPR-Cas systems.
  • The study, entitled Harnessing Type I CRISPR-Cas Systems for Genome Engineering in Human Cells, was published today in the peer-reviewed scientific journal Nature Biotechnology.
  • In the study, Caribou researchers and their collaborators tested whether the multi-protein Class 1 Type I CRISPR-Cas system could be harnessed for human genome engineering.
  • Caribou Biosciences and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20191118005727/en/

CRISPR Gene Editing Eliminates Herpes Simplex Virus and JC Virus, Demonstrating Feasibility of a Potential Functional Cure

Monday, November 18, 2019 - 5:00pm

EntitledInhibition of HSV-1 Replication In-Vitro and In-Vivo by a Gene Editing Strategy, and CRISPR/Cas9 System as an Agent for Inhibition of Polyomavirus JC Infection, the studies demonstrate the power of gene editing as a potential curative therapy.

Key Points: 
  • EntitledInhibition of HSV-1 Replication In-Vitro and In-Vivo by a Gene Editing Strategy, and CRISPR/Cas9 System as an Agent for Inhibition of Polyomavirus JC Infection, the studies demonstrate the power of gene editing as a potential curative therapy.
  • Researchers working with collaborators at the Lewis Katz School of Medicine at Temple University (LKSOM) demonstrated the ability to remove JC Virus and HSV from cell lines and animals using CRISPR, a powerful gene editing technology.
  • By using CRISPR in unique ways, the company has already demonstrated the first functional cure for HIV in animals.
  • Editors Note: Dr. Khalili is a named inventor on patents that cover the CRISPR/CAS9 system viral gene editing technology.